EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 147 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $214,000 | -42.6% | 4,809 | -36.2% | 0.00% | -33.3% |
| Q1 2022 | $373,000 | -3.4% | 7,543 | -0.5% | 0.01% | -14.3% |
| Q4 2021 | $386,000 | -11.3% | 7,581 | -2.7% | 0.01% | -22.2% |
| Q3 2021 | $435,000 | +61.7% | 7,791 | +24.0% | 0.01% | +80.0% |
| Q2 2021 | $269,000 | +691.2% | 6,282 | +681.3% | 0.01% | +400.0% |
| Q1 2021 | $34,000 | -91.2% | 804 | -91.2% | 0.00% | -91.7% |
| Q3 2020 | $388,000 | -11.6% | 9,119 | -0.1% | 0.01% | -14.3% |
| Q2 2020 | $439,000 | +4.3% | 9,130 | +0.1% | 0.01% | -6.7% |
| Q1 2020 | $421,000 | -24.4% | 9,119 | -1.9% | 0.02% | +25.0% |
| Q4 2019 | $557,000 | +992.2% | 9,295 | +635.4% | 0.01% | +1100.0% |
| Q4 2018 | $51,000 | -84.3% | 1,264 | -73.0% | 0.00% | -85.7% |
| Q3 2018 | $324,000 | -4.4% | 4,676 | +4.3% | 0.01% | 0.0% |
| Q2 2018 | $339,000 | +40.7% | 4,484 | -1.9% | 0.01% | +40.0% |
| Q1 2018 | $241,000 | +24000.0% | 4,571 | +28468.8% | 0.01% | – |
| Q4 2017 | $1,000 | – | 16 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tri Locum Partners LP | 94,922 | $4,063,000 | 1.33% |
| Smith, Graham & Co., Investment Advisors, LP | 277,572 | $11,880,000 | 1.05% |
| Krensavage Asset Management, LLC | 70,804 | $3,030,000 | 1.03% |
| BRANDES INVESTMENT PARTNERS, LP | 716,873 | $30,682,000 | 0.68% |
| GLOBEFLEX CAPITAL L P | 42,357 | $1,813,000 | 0.33% |
| Zebra Capital Management LLC | 6,472 | $277,000 | 0.32% |
| Capital Impact Advisors, LLC | 19,276 | $825,000 | 0.27% |
| Hein Park Capital Management LP | 31,977 | $1,369,000 | 0.26% |
| CHARTWELL INVESTMENT PARTNERS, LLC | 195,340 | $8,361,000 | 0.25% |
| Stanley-Laman Group, Ltd. | 24,000 | $1,027,000 | 0.15% |